TNSN01068A1 - Compositions pharmaceutiques pour le traitement de maladies comportant un dysfonctionnement cognitif - Google Patents
Compositions pharmaceutiques pour le traitement de maladies comportant un dysfonctionnement cognitifInfo
- Publication number
- TNSN01068A1 TNSN01068A1 TNTNSN01068A TNSN01068A TNSN01068A1 TN SN01068 A1 TNSN01068 A1 TN SN01068A1 TN TNSN01068 A TNTNSN01068 A TN TNSN01068A TN SN01068 A TNSN01068 A TN SN01068A TN SN01068 A1 TNSN01068 A1 TN SN01068A1
- Authority
- TN
- Tunisia
- Prior art keywords
- treatment
- cognitive dysfunction
- diseases
- pharmaceutical compositions
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L’INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE COMPRENANT DEUX AGENTS ACTIFS. LE PREMIER AGENT EST UN AGONISTE PARTIEL DES RECEPTEURS DE NICOTINE. LE DEUXIEME AGENT EST UN INHIBITEUR D’ACETYLCHOLINESTERASE, UN INHIBITEUR DE BUTYLCHOLINESTERASE, UN AGENT OESTROGENIQUE, UN MODULATEUR DES RECEPTEURS D’OESTROGENES SELECTIF OU UN AGONISTE MUSCARINIQUE. APPLICATION : UTILISATION POUR LA PREVENTION ET LE TRAITEMENT DE MALADIES COMPORTANT UN DYSFONCTIONNEMENT COGNITIF CHEZ UN MAMMIFERE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20279900P | 2000-05-09 | 2000-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN01068A1 true TNSN01068A1 (fr) | 2005-11-10 |
Family
ID=22751325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN01068A TNSN01068A1 (fr) | 2000-05-09 | 2001-05-08 | Compositions pharmaceutiques pour le traitement de maladies comportant un dysfonctionnement cognitif |
Country Status (16)
Country | Link |
---|---|
US (2) | US20010036949A1 (fr) |
EP (1) | EP1280554A2 (fr) |
JP (1) | JP2003532670A (fr) |
AR (1) | AR028426A1 (fr) |
AU (1) | AU2001248699A1 (fr) |
BR (1) | BR0110487A (fr) |
CA (1) | CA2409720A1 (fr) |
EC (1) | ECSP014065A (fr) |
GT (1) | GT200100075A (fr) |
MX (1) | MXPA02011051A (fr) |
PA (1) | PA8516701A1 (fr) |
PE (1) | PE20011256A1 (fr) |
SV (1) | SV2002000440A (fr) |
TN (1) | TNSN01068A1 (fr) |
UY (1) | UY26693A1 (fr) |
WO (1) | WO2001085145A2 (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
DE60124730T2 (de) | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
JP2004527545A (ja) * | 2001-04-20 | 2004-09-09 | ファイザー・プロダクツ・インク | 1,3−置換インデンおよびアリール縮合アザ多環式化合物の調製方法 |
AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
EP1420773A1 (fr) * | 2001-08-31 | 2004-05-26 | Neurochem (International) Limited | Derives d'amidine destines au traitement de l'amylose |
US20040092427A1 (en) * | 2002-09-25 | 2004-05-13 | Anil Gulati | Method and composition for treating alzheimer's disease and dementias of vascular origin |
WO2005000806A2 (fr) * | 2003-06-10 | 2005-01-06 | Georgetown University | Ligands pour les recepteurs de l'acetylcholine nicotinique, et procedes de production et d'utilisation de ces ligands |
US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
AU2004278414B2 (en) | 2003-10-01 | 2012-05-24 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US20060019938A1 (en) * | 2003-12-31 | 2006-01-26 | Beer Tomasz M | Estrogen administration for treating male cognitive dysfunction or improving male cognitive function |
US7262223B2 (en) * | 2004-01-23 | 2007-08-28 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
US20050182044A1 (en) * | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
AU2005244867A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor |
JP2008500368A (ja) * | 2004-05-27 | 2008-01-10 | ミジェニックス コーポレイション | 細胞保護のための2置換17−イミノエストロゲン化合物 |
EP2258359A3 (fr) * | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline |
EP1928437A2 (fr) * | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenese par modulation du recepteur muscarinique |
US7576207B2 (en) | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
GB0607952D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
CA2662115A1 (fr) | 2006-09-12 | 2008-03-20 | Adolor Corporation | Methodes d'amelioration de la fonction cognitive |
EP2089383B1 (fr) | 2006-11-09 | 2015-09-16 | Probiodrug AG | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
ES2533484T3 (es) | 2007-04-18 | 2015-04-10 | Probiodrug Ag | Derivados de tiourea como inhibidores de la glutaminil ciclasa |
FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
DK2475428T3 (en) | 2009-09-11 | 2015-09-28 | Probiodrug Ag | Heterocyclic derivatives as glutaminylcyklaseinhibitorer |
BR112012019923A2 (pt) | 2010-02-09 | 2016-08-09 | Univ Johns Hopkins | métodos e composições para melhorar a função cognitiva |
WO2011107530A2 (fr) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Nouveaux inhibiteurs |
CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
US8846061B1 (en) | 2011-03-08 | 2014-09-30 | Mark S. Bezzek | Multivitamin-mineral regimens for longevity and wellness |
US8349376B1 (en) | 2011-03-08 | 2013-01-08 | Bezzek Mark S | Anti-dementia regimen |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
US20150031655A1 (en) * | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
CA2891122C (fr) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methodes et compositions pour le traitement de la schizophrenie |
US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
EP3827820A1 (fr) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam pour améliorer la fonction cognitive |
CN112843005B (zh) | 2015-05-22 | 2023-02-21 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
EP3461819B1 (fr) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibiteurs de la glutaminyl-cyclase |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218383B1 (en) * | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
-
2001
- 2001-01-16 US US09/760,966 patent/US20010036949A1/en not_active Abandoned
- 2001-04-24 MX MXPA02011051A patent/MXPA02011051A/es unknown
- 2001-04-24 JP JP2001581799A patent/JP2003532670A/ja active Pending
- 2001-04-24 WO PCT/IB2001/000681 patent/WO2001085145A2/fr not_active Application Discontinuation
- 2001-04-24 AU AU2001248699A patent/AU2001248699A1/en not_active Abandoned
- 2001-04-24 EP EP01921733A patent/EP1280554A2/fr not_active Withdrawn
- 2001-04-24 BR BR0110487-0A patent/BR0110487A/pt not_active IP Right Cessation
- 2001-04-24 CA CA002409720A patent/CA2409720A1/fr not_active Abandoned
- 2001-05-04 GT GT200100075A patent/GT200100075A/es unknown
- 2001-05-07 UY UY26693A patent/UY26693A1/es not_active Application Discontinuation
- 2001-05-08 EC EC2001004065A patent/ECSP014065A/es unknown
- 2001-05-08 SV SV2001000440A patent/SV2002000440A/es not_active Application Discontinuation
- 2001-05-08 PE PE2001000412A patent/PE20011256A1/es not_active Application Discontinuation
- 2001-05-08 TN TNTNSN01068A patent/TNSN01068A1/fr unknown
- 2001-05-08 AR ARP010102169A patent/AR028426A1/es unknown
- 2001-05-09 PA PA20018516701A patent/PA8516701A1/es unknown
-
2003
- 2003-01-21 US US10/347,955 patent/US20030130303A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ECSP014065A (es) | 2003-01-13 |
US20010036949A1 (en) | 2001-11-01 |
US20030130303A1 (en) | 2003-07-10 |
BR0110487A (pt) | 2003-04-01 |
EP1280554A2 (fr) | 2003-02-05 |
CA2409720A1 (fr) | 2001-11-15 |
WO2001085145A8 (fr) | 2001-12-13 |
WO2001085145A2 (fr) | 2001-11-15 |
WO2001085145A3 (fr) | 2002-06-13 |
JP2003532670A (ja) | 2003-11-05 |
PA8516701A1 (es) | 2002-09-17 |
PE20011256A1 (es) | 2001-12-29 |
MXPA02011051A (es) | 2003-03-10 |
UY26693A1 (es) | 2001-12-28 |
SV2002000440A (es) | 2002-10-24 |
GT200100075A (es) | 2001-12-31 |
AU2001248699A1 (en) | 2001-11-20 |
AR028426A1 (es) | 2003-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN01068A1 (fr) | Compositions pharmaceutiques pour le traitement de maladies comportant un dysfonctionnement cognitif | |
TNSN02018A1 (fr) | COMPOSITIONS COMPRENANT UN AGONISTE INVERSE DE GABAa, ET UN AGONISTE PARTIEL DES RECEPTEURS DE NICOTINE, UN OESTROGENE, UN MODULATEUR SELECTIF DES RECEPTEURS D'OESTROGENE OU DE LA VITAMINE E | |
TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
TNSN00183A1 (fr) | COMPOSITIONS COMPRENANT LE POLYPEPTIDE IL-1ra ET UN INHIBITEUR DE MATURATION ET DE LIBERATION DE IL-1 ET METHODES DE TRAITEMENT LES UTILISANT | |
EP1027011A4 (fr) | Administration d'agents actifs, notamment d'agonistes et antagonistes du recepteur de 5-ht, afin de traiter l'ejaculation precoce | |
PT893992E (pt) | Formas de dosagem oral de desintegracao rapida | |
TNSN00093A1 (fr) | Modulateurs nouveaux des recepteurs de glucocorticoides, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA24193A1 (fr) | Procedes pour la preparation de conjugue peg-ifn alpha physiologiquement actif, et pour la preparation de compositions pharmaceutiques le contenant et leur utilisation | |
MA26702A1 (fr) | Compositions pharmaceutiques pour le traitement de la migraine, et procede pour leur preparation | |
TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN00010A1 (fr) | DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE. | |
TNSN01166A1 (fr) | Composes agonistes selectifs des recepteurs ep4 et compositions les contenant. | |
TNSN01119A1 (fr) | Compositions contenant des inhibiteurs de la proteine de transfert d'ester de cholesteryle | |
TNSN01173A1 (fr) | Compositions pharmaceutiques comprenant un antagoniste des recepteurs de nmda. | |
TNSN04268A1 (fr) | UTILISATION D'INHIBITEURS CETP ET FACULTATIVEMENT D'INHIBITEURS DE HMG -CoA - REDUCTASE ET/OU D'AGENTS ANTI-HYPERTENSIFS | |
TNSN97040A1 (fr) | Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation. | |
TNSN04192A1 (fr) | Preparation pharmaceutique contenant de l'oxycodone et du naloxone | |
MA27863A1 (fr) | Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur | |
MA28435B1 (fr) | Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4 | |
UA37259C2 (uk) | Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч | |
MA31089B1 (fr) | Anticorps anti-notch3 antagonistes et utilisations de ces derniers dans la prophylaxie et le traitement de maladies liees a notch3 | |
TNSN98227A1 (fr) | Association pharmaceutique pour le traitement d'un dysfonctionnement sexuel et compositions la contenant. | |
TNSN99135A1 (fr) | Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression | |
CA2325739A1 (fr) | Combinaison destinee au traitement de la dependance a l'alcool et aux drogues contenant un antagoniste d'opioides et un modulateur du complexe du recepteur nmda | |
CA2378613A1 (fr) | Antagonistes selectifs du recepteur iglur5 utilises dans le traitement de la migraine |